Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer

Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein report a 78-year-old w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Intern Med
Main Authors: Nishima, Shunichi, Miyanaga, Akihiko, Saito, Sho, Yuasa, Mizuki, Takahashi, Satoshi, Kashiwada, Takeru, Sugano, Teppei, Noro, Rintaro, Minegishi, Yuji, Terasaki, Yasuhiro, Saito, Yoshinobu, Kubota, Kaoru, Seike, Masahiro, Gemma, Akihiko
Formato: Artigo
Idioma:Inglês
Publicado em: The Japanese Society of Internal Medicine 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7946498/
https://ncbi.nlm.nih.gov/pubmed/32999231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.5435-20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados